Japan's biggest drugmaker said it will incur restructuring costs of about 140 billion yen ($899 million) this fiscal year as ...

Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi ...

Merck said on Thursday its therapy did not meet the main goal of disease-free survival in certain patients with endometrial cancer during a late-stage trial. The drugmaker's Keytruda therapy in ...

Merck continues to make tremendous progress in developing its rich portfolio of experimental drugs and vaccines. As a result, ...

Its second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Most Read from BloombergMicrosoft’s Xbox Is ...

Much of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a decision expected in a matter ...

There’s long been a global shortage of the BCG vaccine for bladder cancer. But since ImmunityBio won FDA approval for Anktiva, an immunotherapy meant to be used along with the BCG vaccine, production ...

Customized with genetic information from a patient’s own tumor, vaccines like this could one day be used against lung, kidney ...

Drug major Merck & Co., Inc. (MRK) announced Thursday that the Phase 3 KEYNOTE-B21 trial evaluating its anti-PD-1 therapy KEYTRUDA ...

After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just ...

Merck (MRK) stock slipped as a Phase 3 trial for Keytruda with chemotherapy as a first-line option fails in endometrial ...

BCG, originally developed as a tuberculosis vaccine, is also a standard treatment for NMIBC ... Soon-Shiong's ImmunityBio bags FDA approval for Anktiva to challenge Merck in bladder cancer Merck’s ...